Based on the knowledge of the biological effects induced by the PD-1/PD-L1 interaction, immunotherapy drugs have been designed to block ligand–receptor binding and improve the ability of the CD8+ T lymphocytes to identify and eliminate malignant tumor cells. This evidence concerns the gene CD8A and cancer.